ASA 81 mg vs 162 mg During Frozen Embryo Transfer (FET)

Ovo Clinic

Status

Completed

Conditions

Fertility Disorders

Treatments

Other: Frozen embryo transfer

Study type

Observational

Funder types

Industry

Identifiers

NCT06128395

3384

Details and patient eligibility

About

The use of low dose aspirin is recommended for high risk patients to reduce the risk of pre-eclampsia, placental abruption and antepartum hemorrhage. Recent studies have shown that in a specific population, the use of low dose aspirin might reduce the risk of preterm birth in pregnant women with singleton pregnancy. In June 2022, clinique ovo started implementing the use of Aspirin 162 mg instead of 81 mg in the frozen embryo transfer cycles based on recent study outcomes. The use of Aspirin 162 mg might have additional benefits on the embryo transfer outcomes by decreasing the miscarriage. Moreover this can be continued until late in pregnancy without adverse effects.

Enrollment

1,207 patients

Sex

Female

Ages

Under 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Women taking aspirin 81 mg or 162 mg prior to an autologous embryo transfer
Age < 40 years old
Embryo transfer cycle done at clinique ovo

Exclusion criteria

Egg or embryo recipient
History of recurrent miscarriages, defined as ≥ 3 consecutive losses
Patients that needed Viagra, PRP or other modalities to improve their endometrial thickness
Uterine factor infertility
Abnormal hormonal profiles
Stimulated embryo transfer cycles
History of recurrent implantation failure defined as failed ≥ 2 euploid embryos transfer or ≥ 3 blastocysts